Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)

<p>Abstract</p> <p>Background</p> <p>Severe hypoglycaemia (SH) is one of the most feared complications of type 1 diabetes (T1DM) with a reported prevalence of nearly 40%. In randomized trials of Multiple Daily Injections (MDI) and Continuous Subcutaneous Insulin Infusio...

Full description

Bibliographic Details
Main Authors: Little Stuart, Chadwick Thomas, Choudhary Pratik, Brennand Cath, Stickland Julia, Barendse Shalleen, Olateju Tolulope, Leelarathna Lalantha, Walkinshaw Emma, Tan Horng K, Marshall Sally M, Thomas Reena M, Heller Simon, Evans Mark, Kerr David, Flanagan Daniel, Speight Jane, Shaw James AM
Format: Article
Language:English
Published: BMC 2012-12-01
Series:BMC Endocrine Disorders
Online Access:http://www.biomedcentral.com/1472-6823/12/33
_version_ 1811267140793139200
author Little Stuart
Chadwick Thomas
Choudhary Pratik
Brennand Cath
Stickland Julia
Barendse Shalleen
Olateju Tolulope
Leelarathna Lalantha
Walkinshaw Emma
Tan Horng K
Marshall Sally M
Thomas Reena M
Heller Simon
Evans Mark
Kerr David
Flanagan Daniel
Speight Jane
Shaw James AM
author_facet Little Stuart
Chadwick Thomas
Choudhary Pratik
Brennand Cath
Stickland Julia
Barendse Shalleen
Olateju Tolulope
Leelarathna Lalantha
Walkinshaw Emma
Tan Horng K
Marshall Sally M
Thomas Reena M
Heller Simon
Evans Mark
Kerr David
Flanagan Daniel
Speight Jane
Shaw James AM
author_sort Little Stuart
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Severe hypoglycaemia (SH) is one of the most feared complications of type 1 diabetes (T1DM) with a reported prevalence of nearly 40%. In randomized trials of Multiple Daily Injections (MDI) and Continuous Subcutaneous Insulin Infusion (CSII) therapy there is a possible benefit of CSII in reducing SH. However few trials have used basal insulin analogues as the basal insulin in the MDI group and individuals with established SH have often been excluded from prospective studies. In published studies investigating the effect of Real Time Continuous Glucose Monitoring (RT-CGM) benefit in terms of reduced SH has not yet been demonstrated. The primary objective of this study is to elucidate whether in people with T1DM complicated by impaired awareness of hypoglycaemia (IAH), rigorous prevention of biochemical hypoglycaemia using optimized existing self-management technology and educational support will restore awareness and reduce risk of recurrent SH.</p> <p>Methods/design</p> <p>This is a multicentre prospective RCT comparing hypoglycaemia avoidance with optimized MDI and CSII with or without RT-CGM in a 2×2 factorial design in people with type 1 diabetes who have IAH. The primary outcome measure for this study is the difference in IAH (Gold score) at 24 weeks. Secondary outcomes include biomedical measures such as HbA1c, SH incidence, blinded CGM analysis, self monitored blood glucose (SMBG) and response to hypoglycaemia in gold standard clamp studies. Psychosocial measures including well-being and quality of life will also be assessed using several validated and novel measures. Analysis will be on an intention-to-treat basis.</p> <p>Discussion</p> <p>Most existing RCTs using this study’s interventions have been powered for change in HbA1c rather than IAH or SH. This trial will demonstrate whether IAH can be reversed and SH prevented in people with T1DM in even those at highest risk by using optimized conventional management and existing technology.</p> <p>Trial Registration</p> <p>ISRCTN52164803 Eudract No: 2009-015396-27</p>
first_indexed 2024-04-12T20:57:08Z
format Article
id doaj.art-9950adf7a3ad44c5b2b7394e96718cb7
institution Directory Open Access Journal
issn 1472-6823
language English
last_indexed 2024-04-12T20:57:08Z
publishDate 2012-12-01
publisher BMC
record_format Article
series BMC Endocrine Disorders
spelling doaj.art-9950adf7a3ad44c5b2b7394e96718cb72022-12-22T03:16:58ZengBMCBMC Endocrine Disorders1472-68232012-12-011213310.1186/1472-6823-12-33Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)Little StuartChadwick ThomasChoudhary PratikBrennand CathStickland JuliaBarendse ShalleenOlateju TolulopeLeelarathna LalanthaWalkinshaw EmmaTan Horng KMarshall Sally MThomas Reena MHeller SimonEvans MarkKerr DavidFlanagan DanielSpeight JaneShaw James AM<p>Abstract</p> <p>Background</p> <p>Severe hypoglycaemia (SH) is one of the most feared complications of type 1 diabetes (T1DM) with a reported prevalence of nearly 40%. In randomized trials of Multiple Daily Injections (MDI) and Continuous Subcutaneous Insulin Infusion (CSII) therapy there is a possible benefit of CSII in reducing SH. However few trials have used basal insulin analogues as the basal insulin in the MDI group and individuals with established SH have often been excluded from prospective studies. In published studies investigating the effect of Real Time Continuous Glucose Monitoring (RT-CGM) benefit in terms of reduced SH has not yet been demonstrated. The primary objective of this study is to elucidate whether in people with T1DM complicated by impaired awareness of hypoglycaemia (IAH), rigorous prevention of biochemical hypoglycaemia using optimized existing self-management technology and educational support will restore awareness and reduce risk of recurrent SH.</p> <p>Methods/design</p> <p>This is a multicentre prospective RCT comparing hypoglycaemia avoidance with optimized MDI and CSII with or without RT-CGM in a 2×2 factorial design in people with type 1 diabetes who have IAH. The primary outcome measure for this study is the difference in IAH (Gold score) at 24 weeks. Secondary outcomes include biomedical measures such as HbA1c, SH incidence, blinded CGM analysis, self monitored blood glucose (SMBG) and response to hypoglycaemia in gold standard clamp studies. Psychosocial measures including well-being and quality of life will also be assessed using several validated and novel measures. Analysis will be on an intention-to-treat basis.</p> <p>Discussion</p> <p>Most existing RCTs using this study’s interventions have been powered for change in HbA1c rather than IAH or SH. This trial will demonstrate whether IAH can be reversed and SH prevented in people with T1DM in even those at highest risk by using optimized conventional management and existing technology.</p> <p>Trial Registration</p> <p>ISRCTN52164803 Eudract No: 2009-015396-27</p>http://www.biomedcentral.com/1472-6823/12/33
spellingShingle Little Stuart
Chadwick Thomas
Choudhary Pratik
Brennand Cath
Stickland Julia
Barendse Shalleen
Olateju Tolulope
Leelarathna Lalantha
Walkinshaw Emma
Tan Horng K
Marshall Sally M
Thomas Reena M
Heller Simon
Evans Mark
Kerr David
Flanagan Daniel
Speight Jane
Shaw James AM
Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
BMC Endocrine Disorders
title Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
title_full Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
title_fullStr Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
title_full_unstemmed Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
title_short Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
title_sort comparison of optimised mdi versus pumps with or without sensors in severe hypoglycaemia the hypo compass trial
url http://www.biomedcentral.com/1472-6823/12/33
work_keys_str_mv AT littlestuart comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT chadwickthomas comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT choudharypratik comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT brennandcath comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT sticklandjulia comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT barendseshalleen comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT olatejutolulope comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT leelarathnalalantha comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT walkinshawemma comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT tanhorngk comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT marshallsallym comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT thomasreenam comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT hellersimon comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT evansmark comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT kerrdavid comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT flanagandaniel comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT speightjane comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial
AT shawjamesam comparisonofoptimisedmdiversuspumpswithorwithoutsensorsinseverehypoglycaemiathehypocompasstrial